Lizi Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lizi Wu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Jingxuan Liu
Department of Medical Oncology, Dana-Farber Cancer Institute and Departments of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
3 shared publicationsPing Gao
Department of Medical Oncology, Dana-Farber Cancer Institute and Departments of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
3 shared publicationsHuangxuan Shen
Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
2 shared publicationsJames D. Griffin
Department of Medical Oncology, Dana-Farber Cancer Institute and Departments of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
2 shared publicationsMakoto Nakamura
Department of Medical Oncology, Dana‐Farber Cancer Institute Boston MA USA
2 shared publicationsYang Cao
Department of Medical Oncology, Dana-Farber Cancer Institute and Departments of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
2 shared publications
Latest Publications
- Open Access
- 1 March 2006
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 20 (6) , 675-688
The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis
The MAML (mastermind-like) proteins are a family of three cotranscriptional regulators that are essential for Notch signaling, a pathway critical for cell fate determination. Though the functions of MAML proteins in normal development remain unresolved, their distinct tissue distributions and differential activities in cooperating with various Notch receptors suggest that they have unique roles. Here we show that mice with a targeted disruption of the Maml1 gene have severe muscular dystrophy. In vitro, Maml1-null embryonic fibroblasts failed to undergo MyoD-induced myogenic differentiation, further suggesting that Maml1 is required for muscle development. Interestingly, overexpression of MAML1 in C2C12 cells dramatically enhanced myotube formation and increased the expression of muscle-specific genes, while RNA interference (RNAi)-mediated MAML1 knockdown abrogated differentiation. Moreover, we determined that MAML1 interacts with MEF2C (myocyte enhancer factor 2C), functioning as its potent cotranscriptional regulator. Surprisingly, however, MAML1’s promyogenic effects were completely blocked upon activation of Notch signaling, which was associated with recruitment of MAML1 away from MEF2C to the Notch transcriptional complex. Our study thus reveals novel and nonredundant functions for MAML1: It acts as a coactivator for MEF2C transcription and is essential for proper muscle development. Mechanistically, MAML1 appears to mediate cross-talk between Notch and MEF2 to influence myogenic differentiation.
- 1 March 2006
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 20 (6) , 675-688
Open AccessThe Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis
The MAML (mastermind-like) proteins are a family of three cotranscriptional regulators that are essential for Notch signaling, a pathway critical for cell fate determination. Though the functions of MAML proteins in normal development remain unresolved, their distinct tissue distributions and differential activities in cooperating with various Notch receptors suggest that they have unique roles. Here we show that mice with a targeted disruption of the Maml1 gene have severe muscular dystrophy. In vitro, Maml1-null embryonic fibroblasts failed to undergo MyoD-induced myogenic differentiation, further suggesting that Maml1 is required for muscle development. Interestingly, overexpression of MAML1 in C2C12 cells dramatically enhanced myotube formation and increased the expression of muscle-specific genes, while RNA interference (RNAi)-mediated MAML1 knockdown abrogated differentiation. Moreover, we determined that MAML1 interacts with MEF2C (myocyte enhancer factor 2C), functioning as its potent cotranscriptional regulator. Surprisingly, however, MAML1’s promyogenic effects were completely blocked upon activation of Notch signaling, which was associated with recruitment of MAML1 away from MEF2C to the Notch transcriptional complex. Our study thus reveals novel and nonredundant functions for MAML1: It acts as a coactivator for MEF2C transcription and is essential for proper muscle development. Mechanistically, MAML1 appears to mediate cross-talk between Notch and MEF2 to influence myogenic differentiation.
- Open Access
- 16 June 2005
- Published by Springer Nature in The EMBO Journal
- Vol. 24 (13) , 2391-2402
Transforming activity of MECT1‐MAML2 fusion oncoprotein is mediated by constitutive CREB activation
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 16 June 2005
- Published by Springer Nature in The EMBO Journal
- Vol. 24 (13) , 2391-2402
Open AccessTransforming activity of MECT1‐MAML2 fusion oncoprotein is mediated by constitutive CREB activation
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.